Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
https://www.zacks.com/stock/news/2275562/pharma-stock-roundup-bayry-s-q1-earnings-jnj-s-new-buyout-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275562
May 17, 2024 - Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
0
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
https://www.fool.com/investing/2024/05/17/meet-the-glp-1-drug-that-could-be-the-biggest-conc/?source=iedfolrf0000001
May 17, 2024 - Could Amgen be the next stock to soar due to a GLP-1 drug?
0
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
https://www.zacks.com/stock/news/2274860/roche-rhhby-posts-encouraging-phase-i-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274860
May 16, 2024 - Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
0
These 2 No-Brainer Growth Stocks Are Breaking New Ground
https://www.fool.com/investing/2024/05/16/these-2-no-brainer-growth-stocks-are-breaking-new/?source=iedfolrf0000001
May 16, 2024 - The future keeps getting brighter for these companies.
0
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
https://www.zacks.com/stock/news/2274368/biogen-biib-partner-begins-filing-for-leqembi-sc-autoinjector?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274368
May 15, 2024 - Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
0
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
https://www.zacks.com/stock/news/2274187/eli-lilly-lly-settles-with-spa-selling-mounjaro-zepbound-copies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274187
May 15, 2024 - Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
0
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
https://www.zacks.com/stock/news/2272311/pharma-stock-roundup-pfe-dmd-study-patient-death-fda-panel-meet-for-lly-s-donanemab?cid=CS-ZC-FT-analyst_blog|stock_roundup-2272311
May 10, 2024 - Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
0
A Look at Pharma ETFs Post Q1 Earnings
https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782
May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
0
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
https://www.fool.com/investing/2024/05/05/3-super-safe-dividend-stocks-that-have-been-making/?source=iedfolrf0000001
May 05, 2024 - These stocks have rock-solid businesses and they have impressive track records for paying dividends.
0
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
https://www.fool.com/investing/2024/05/04/move-over-mounjaro-eli-lilly-has-another-blockbust/?source=iedfolrf0000001
May 04, 2024 - Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.
0